O Arguedas

575 total citations
9 papers, 187 citations indexed

About

O Arguedas is a scholar working on Hematology, Speech and Hearing and Rheumatology. According to data from OpenAlex, O Arguedas has authored 9 papers receiving a total of 187 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hematology, 4 papers in Speech and Hearing and 4 papers in Rheumatology. Recurrent topics in O Arguedas's work include Autoimmune and Inflammatory Disorders Research (6 papers), Adolescent and Pediatric Healthcare (4 papers) and Pediatric health and respiratory diseases (2 papers). O Arguedas is often cited by papers focused on Autoimmune and Inflammatory Disorders Research (6 papers), Adolescent and Pediatric Healthcare (4 papers) and Pediatric health and respiratory diseases (2 papers). O Arguedas collaborates with scholars based in Costa Rica, Italy and Argentina. O Arguedas's co-authors include Anders Fasth, Boel Andersson‐Gäre, O. Porras, Silvia Magni‐Manzoni, Bianca Lattanzi, E Castell, Angela Pistorio, Sara Verazza, Nicolino Ruperto and Alessandra Magnani and has published in prestigious journals such as Pediatric Rheumatology, JCR Journal of Clinical Rheumatology and Arthritis & Rheumatism.

In The Last Decade

O Arguedas

9 papers receiving 181 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
O Arguedas Costa Rica 5 167 75 75 44 42 9 187
S Dalprà Italy 5 224 1.3× 131 1.7× 66 0.9× 43 1.0× 53 1.3× 11 244
Sara Verazza Italy 6 210 1.3× 121 1.6× 63 0.8× 47 1.1× 56 1.3× 11 238
Alessandra Alongi Italy 6 127 0.8× 52 0.7× 53 0.7× 33 0.8× 25 0.6× 13 154
Ina Liedmann Germany 5 172 1.0× 72 1.0× 84 1.1× 36 0.8× 14 0.3× 10 214
C. Ryder United Kingdom 4 241 1.4× 123 1.6× 78 1.0× 55 1.3× 78 1.9× 6 265
Timothy G. Brandon United States 10 222 1.3× 50 0.7× 212 2.8× 94 2.1× 46 1.1× 26 301
Е. G. Chistyakova Russia 5 91 0.5× 59 0.8× 30 0.4× 27 0.6× 21 0.5× 19 127
Manuel Salgado Portugal 7 52 0.3× 20 0.3× 38 0.5× 26 0.6× 25 0.6× 32 128
Maja Bulatović Netherlands 6 178 1.1× 104 1.4× 69 0.9× 19 0.4× 20 0.5× 9 260
Adriana Ivonne Céspedes-Cruz Mexico 5 103 0.6× 75 1.0× 41 0.5× 15 0.3× 28 0.7× 10 140

Countries citing papers authored by O Arguedas

Since Specialization
Citations

This map shows the geographic impact of O Arguedas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by O Arguedas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites O Arguedas more than expected).

Fields of papers citing papers by O Arguedas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by O Arguedas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by O Arguedas. The network helps show where O Arguedas may publish in the future.

Co-authorship network of co-authors of O Arguedas

This figure shows the co-authorship network connecting the top 25 collaborators of O Arguedas. A scholar is included among the top collaborators of O Arguedas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with O Arguedas. O Arguedas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
2.
Ravelli, Angelo, Giulia Varnier, Sheila Knupp Feitosa de Oliveira, et al.. (2010). Antinuclear antibody–positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthritis & Rheumatism. 63(1). 267–275. 96 indexed citations
3.
Verazza, Sara, Bianca Lattanzi, S Dalprà, et al.. (2008). Time of onset of iridocyclitis (IC) in children with juvenile idiopathic arthritis (JIA). Pediatric Rheumatology. 6(S1). 4 indexed citations
4.
García, Paula, Angelo Ravelli, Angela Pistorio, et al.. (2006). ANTINUCLEAR ANTIBODY POSITIVITY IS THE BEST PREDICTOR OF RESPONSE TO METHOTREXATE IN JUVENILE IDIOPATHIC ARTHRITIS. ANALYSIS OF THE PRINTO TRIAL. JCR Journal of Clinical Rheumatology. 12(Supplement). S12–S13. 1 indexed citations
5.
Arguedas, O, Anders Fasth, & Boel Andersson‐Gäre. (2002). A prospective population based study on outcome of juvenile chronic arthritis in Costa Rica.. PubMed. 29(1). 174–83. 21 indexed citations
6.
Arguedas, O. (2001). Juvenile chronic arthritis. A study on epidemiology and outcome in Costa Rican children. Gothenburg University Publications Electronic Archive (Gothenburg University). 1 indexed citations
7.
Arguedas, O, Anders Fasth, Boel Andersson‐Gäre, & O. Porras. (1998). Juvenile chronic arthritis in urban San José, Costa Rica: a 2 year prospective study.. PubMed. 25(9). 1844–50. 38 indexed citations
8.
Arguedas, O, Boel Andersson‐Gäre, Anders Fasth, & O. Porras. (1997). Development of a Costa Rican version of the Childhood Health Assessment Questionnaire.. PubMed. 24(11). 2233–41. 14 indexed citations
9.
Arguedas, O, O. Porras, & Anders Fasth. (1995). Juvenile chronic arthritis in Costa Rica. A pilot referral study.. PubMed. 13(1). 119–23. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026